Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAN study of rocuronium versus placebo in pediatric ARDS
NL-OMON46725Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Rocuronium bromide with Placebo (2 arms). Primary endpoint: Cumulative respiratory morbidity score at 12 months after PICU discharge. Started Dec 2019; status: active, not recruiting.
02
Drugs
rocuronium
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NL-OMON46725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46725.